⏱ 1 min read By ROI-NJ ✔
Published: • Updated:
Text:

Rahway-based Merck & Co. and Isomorphic Labs, a London-based AI-first drug design and development company, announced Nov. 19 a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data resources and discovery experience.

The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) and incorporating select proprietary data sets supplied by Merck for this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.

Read Full Article at ROI-NJ: Merck and British firm Isomorphic Labs agree to strategic research collaboration

Inspira Health Community Resource Van
Inspira Health launches community resource van to expand health care access - Inspira Health announced Nov. 18 the launch of its community resource van to deliver critically needed health care resources to individuals and families in Cumberland, Gloucester and Salem counties.
Thomas H. Glocer Merck
Glocer to retire from Merck Board of Directors in May 2027, will be succeeded by Baker Jr. - Pharmaceutical giant Merck & Co. announced Nov. 18 that Thomas H. Glocer plans to retire from the company’s board of directors at Merck’s annual shareholders’ meeting in May 2027.